Helping clients achieve their business goals by protecting innovations from concept to commercial product
Dr. Rin-Laures draws on three decades of experience to help biopharma clients achieve their intellectual property and business goals. She has managed patent portfolios for nine FDA-approved drugs and provided strategic counseling to a variety of clients from start-ups to Fortune 500 companies. She advises clients on complex intellectual property issues, including PTAB proceedings, oppositions, and patent strategy relating to new pharmaceutical/biotechnology product development, as well as the interface with FDA regulations and related exclusivity provisions. She has extensive experience in negotiating licenses and strategic alliances, and has presented to the Board of Directors of a number of privately and publicly held companies.
Other awards and recognition:
Professional Organization Involvement
"Lily has been instrumental in helping BioMarin to establish patent portfolios for many of BioMarin’s biologic and small molecule programs. Because of her deep scientific knowledge and extensive legal experience, Lily has been successful in obtaining issuance of patents that provide value in extending and supporting market exclusivity of many Company products. . . . Because of her combined corporate and patent legal background and experience as an Executive In-house Counsel, Lily has the ability to provide a global perspective that incorporates patent strategy with business objectives and corporate goals."
Luisa Bigornia, Ph.D., Vice President of Intellectual Property, BioMarin Pharmaceutical Inc.
"Lily has been a unique partner and colleague in helping our company build its strong patent estate. She is sharp, thoughtful, creative and very effective. We would not be where we are if it wasn’t for Lily and her team."
Carlos Paya, former CEO, Immune Design Corporation
"Lily consistently provides creative counselling tempered with integrity and practicality to achieve optimum outcomes for her clients. A natural communicator, she is responsive, good humoured and able to convey complex strategic and tactical thinking and advice in a manner that makes decision making simple for the client. A first-rate attorney . . . I wouldn't exchange her for anyone."
Phillip Ansell, retired Associate General Patent Counsel at a Forbes Global 2000 company
Prosecuted patents relating to Amgen's ENBREL product, including successfully arguing an appeal within the patent office.
Advise CRISPR Therapeutics on intellectual property in the CRISPR-Cas9 field since its formation. Represent involved party as co-lead counsel in Interference Nos. 106,115, 106,127 and 106,132 relating to CRISPR-Cas9 technology.
Copyright © 2022 RinLauresLLC - All Rights Reserved.